• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

CHEST Annual Meeting 2024

October 06 - 09, 2024

  1. AIRSUPRA (albuterol/budesonide)
  2. BREZTRI (budesonide/glycopyrronium/formoterol)
  3. FASENRA (benralizumab)
  4. TEZSPIRE (tezepelumab)

PDF

Lessons from bench to bedside: Exploring genomic and non-genomic mechanisms of albuterol-budesonide as needed for treatment and prevention of acute airway obstruction (ALTA)

PDF

Severe Exacerbations in Patients Following Improved Adherence to Inhaled Corticosteroid-Containing Asthma Maintenance Medications Versus Not: A US Claim-Based Study

HTML

Efficacy of albuterol-budesonide rescue on top of inhaled corticosteroid/long-acting β-agonist (LABA) asthma maintenance therapy containing formoterol or other LABA (MANDALA)

HTML

Efficacy of albuterol-budesonide rescue in patients with moderate-to-severe asthma by smoking history (former vs never): Analysis of MANDALA

PDF

Perspectives on Clinical Discharge Protocols and the Initiation of Single-Inhaler Triple Therapy Following Severe COPD Exacerbations in the United States: An eDelphi Study

PDF

Reduced Risk of Cardiopulmonary Events for COPD Patients Initiating Budesonide/Glycopyrrolate/ Formoterol vs Multiple Inhaler Triple Therapy in the US: The SKOPOS-MAZI Study

PDF

Pulmonary and Cardiovascular Involvement and Persistent Damage in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Analysis of US Health Insurance Claims Data

PDF

Long-term remission and outcomes in patients with severe eosinophilic asthma (SEA) receiving benralizumab: MELTEMI post-hoc analysis

HTML

Efficacy of tezepelumab in patients with severe, uncontrolled asthma and allergic rhinitis grouped by baseline blood eosinophil count: pooled analysis of PATHWAY and NAVIGATOR

HTML

Effect of tezepelumab on patient-reported activity levels and sleep disturbance in patients with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study

HTML

Efficacy of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease by blood eosinophil count and smoking history: phase 2a COURSE study

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice